-transparent.png){kind=logo}
Azimexon, a 2-cyan-aziridinyl immune modulator, was given at a dose of 250 mg/m2/day for 10 days IV to 12 patients with AIDS and 16 with AIDS related complex (ARC). A decrease in total number of AIDS related symptoms from 43 to 24 and in mean number from 2.6 to 1.5 was observed among ARC patients (p less than .01). The most commonly improved symptoms were diarrhea, fatigue, and weight loss with the least frequently improved being lymphadenopathy. The following improvements in immune parameters were observed among ARC patients. DTH to recall antigens improved with an increase in number of positive tests from 35 to 47 and in mean number of positive skin tests from 2.2 on day 0 to 2.9 on day 14 (P less than .05). The geometric mean of the absolute lymphocyte count was 1.395 X 10(3)/microliter on day 0 with a significant increase of 18.0 percent on day 5 (P less than .01) and a 7.7 percent increase on day 21. The geometric mean of the OKT4+ cells on day 0 was 0.250 X 10(3)/microliter with a 33.3 percent increase on day 5 (P less than .07) and a 14.1 percent increase on day 21. T4/T8 ratio increased by 32.7 percent on day 5 (P less than .05) and by 19.4 percent on day 21 from an initial geometric mean of 0.339 X 10(3)/microliter on day 0. The geometric mean of GVH responses increased by 18.2 percent on day 5 (P less than .05) and by 24.0 percent on day 21 (P less than .07) from an initial value of 41.04 mm3. No symptomatic or immunologic improvements were observed among AIDS patients, but rather a significant decrease in mitogenic responses. PHA responses decreased by 70.3 percent on day 5 (P less than .05) and 42.2 percent on day 21 from an initial geometric mean of 4.02 X 10(3) cpm/10(3). Con-A responses decreased by 75.1 percent on day 5 (P less than .05) and increased by 20.3 percent on day 21 from an initial value of 1.14 X 10(3)/10(5) cells. Pretreatment number of absolute OKT4+ cells was the most significant prognostic survival variable. Thus, 8/9 patients with less than 0.10 X 10(3) OKT4+ blood cell/microliter subsequently died as compared to only 1/17 with greater than or equal to 0.10 X 10(3) OKT4+ cells (p less than .001). The only toxic effect of this treatment was mild hemolysis which disappeared upon cessation of treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
April 1986,
The Journal of pediatrics,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
April 1985,
Clinical and experimental immunology,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
January 1985,
Advances in experimental medicine and biology,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
June 1989,
Thrombosis and haemostasis,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
December 1987,
European journal of epidemiology,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
September 1987,
The American journal of medicine,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
May 1987,
The American journal of medicine,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
January 1989,
Journal of pharmaceutical and biomedical analysis,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
October 1985,
Developmental medicine and child neurology,
Y Z Patt, and
P W Mansell, and
J M Reuben, and
L Claghorn, and
S Li, and
E Gehan, and
E M Hersh
March 1987,
Journal of clinical & laboratory immunology,
